Journal Mobile Options
Table of Contents
Vol. 4, No. 2, 2001
Issue release date: November 2001
Community Genet 2001;4:77–80

The Human Genome Project, Genetics and Health

Baird P.
Department of Medical Genetics, University of British Columbia, Vancouver, Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Three main reasons why a genetic approach is unlikely to be a solution to common diseases in the foreseeable future are discussed. The first is the great importance of environmental circumstances in determining health, the second reason is the great complexity of gene/gene, gene/environment interactions, and the third reason is human behavior with regard to compliance with medical recommendations. Since particular interests are likely to push for a genetic approach to disease, there will be a need to protect the public interest so that premature and inappropriate use of genetics is not made, and so that a balanced opportunity to better the health of all is not missed.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Collins FS: Shattuck Lecture – Medical and societal consequences of the Human Genome Project. N Engl J Med 1999;341:28–37.
  2. Collins F: The next 40 years in medicine. Genet Eng News 2000;20/14.
  3. Karanjawal ZE, Collins FS: Genetics in the context of medical practice. JAMA 1998;280:1533–1534.
  4. Bell J: The new genetics in clinical practice. BMJ 1998;316:618–620.
  5. Hawkes CH: Twin studies in medicine – What do they tell us? Q J Med 1997;90:311–321.
  6. Marmot MG, et al: Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: Prevalence of coronary and hypertension heart disease and associated risk factors. Am J Epidemiol 1975;102:514–525.
  7. Kaplan GA, Pamuk E, Lynch JW, Cohen RD, Balfour JL: Income inequality and mortality in the United States: Analysis of mortality and potential pathways. BMJ 1996;312:1004–1007.
  8. Wilkinson RG: Income distribution and life expectancy. BMJ 1992;304:165–168.
  9. Lynch JW, Kaplan GA, Pamuk ER, Cohen RD, Heck KE, Balfour JL, et al: Income inequality and mortality in metropolitan areas of the United States. Am J Public Health 1998;88:1074–1080.
  10. Keating DP, Hertzman C: Developmental Health and the Wealth of Nations. New York, Gilford Press, 1999, chap 1 and 2.
  11. Sijbrands EJG, Westendorp RGJ, Defesche JC, de Meier PHEM, Smelt AHM, Kastelein P: Mortality over two centuries in large pedigree with familial hypercholesterolemia: Family tree mortality study. BMJ 2001;322:1019–1023.
  12. Weatherall D: From genotype to phenotype: Genetics and medical practice in the new millennium. Philos Trans R Soc Lond B Biol Sci 1999;345:1995–2010.

    External Resources

  13. Yan H, Kinzler KW, Vogelstein B: Genetic testing – Present and future. Science 2000;289:1890–1892.
  14. Suomi S: Developmental trajectories, early experiences, and community consequences: Lessons from studies with rhesus monkeys; in Keating D, Hertzman C (eds): Developmental Health and the Wealth of Nations. New York, Gilford Press, 1999, chap 9, pp 185–200.
  15. Treacy E, Childs B, Scriver CR: Response to treatment in hereditary metabolic disease. 1993 survey and 10-year comparison. Am J Hum Genet 1995;56:359–367.
  16. Balmain A, Nagase H: Cancer resistance genes in mice: Models for the study of tumour modifiers. Trends Genet 1998;14:139–144.

    External Resources

  17. Vineis P, Malats N, Lang M, et al: Metabolic Polymorphisms and Susceptibility to Cancer. Lyon, IARC Scientific Publication, 1999, p 148.
  18. Vineis P, McMichael AJ: Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the etiology of colon cancer. Cancer Causes Control 1996;7:479–486.

    External Resources

  19. The Genome International Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature 2001;409:860–921.
  20. Venter JC, et al: The sequence of the human genome. Science 2001;291:1304–1365.
  21. Editorial: The human genome, in proportion. Lancet 2001;357:489.
  22. Seshardi S, Brachman DA, Pilla DF: Apolipoprotein E at 4 allele and the lifetime risk of Alzheimer’s disease. What physicians know, and what they should know. Arch Neurol 1995;52:1074–1079.
  23. Holtzman NA, Marteau TM: Will genetics revolutionize medicine? N Engl J Med 2000;343:141–144.
  24. Horrobin DF: Innovation in the pharmaceutical industry. J R Soc Med 2000;93:341–345.
  25. Becker MH: Patient adherence to prescribed therapies. Med Care 1985;23:539–555.
  26. Lerman C, Gold K, Audrain J, Lin TH, Boyd NR, Orleans CT, et al: Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: Effects on smoking-related cognitions, emotions, and behavior change. Health Psychol 1997;16:87–99.
  27. Kahneman D, Tversky A: The psychology of preferences. Sci Am 1982;246:160, 164.
  28. Wertz DC: Society and the not-so-new genetics: What are we afraid of? Some future predictions from a social scientist. J Contemp Health Law Policy 1997;13:299–345.
  29. Herman C, Hughes C, Trock BJ, et al: Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 1999;281:1618–1622.
  30. Harris R, Lane B, Harris H, Williamson P, Dodge J, Modell B, et al: National confidential enquiry into counselling for genetic disorders by non-geneticists: General recommendations and specific standards for improving. Br J Obstet Gynaecol 1999;106:658–663.
  31. Hunter A, Wright P, Cappelli M, Kasaboski A, Surh L: Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Clin Genet 1998;53:447–455.
  32. Rose G: Sick individuals and sick populations. Int J Epidemiol 1985;14:32–38.
  33. Baird PA: Genetic technologies and achieving health for populations. Int J Health Serv 2000;30:407–424.
  34. Baird PA: Will genetics be used wisely? ISUMA Can J Policy Res 2001;2:94–101.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00